标题
Oncogenic signaling in uveal melanoma
作者
关键词
-
出版物
Pigment Cell & Melanoma Research
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-05-08
DOI
10.1111/pcmr.12708
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- (2018) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma
- (2018) Amanda R. Moore et al. Cell Reports
- miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN
- (2017) J.W. Ling et al. GENETICS AND MOLECULAR RESEARCH
- Roles of Arf6 in cancer cell invasion, metastasis and proliferation
- (2017) Rui Li et al. LIFE SCIENCES
- Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
- (2017) Hanyin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics
- (2017) Fiona P. Bailey et al. Pigment Cell & Melanoma Research
- A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.
- (2017) J. F. Pingpank et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing
- (2016) Beryl Royer-Bertrand et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
- (2016) F Mouriaux et al. BRITISH JOURNAL OF CANCER
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma
- (2016) Jae Hyuk Yoo et al. CANCER CELL
- A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
- (2016) Alexander N. Shoushtari et al. MELANOMA RESEARCH
- Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
- (2016) Amanda R Moore et al. NATURE GENETICS
- Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
- (2016) Sophie Piperno-Neumann et al. ONCOLOGIST
- Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
- (2016) Guillaume Carita et al. Oncotarget
- Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish
- (2016) Mai Abdel Mouti et al. Oncotarget
- Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQQ209L-driven melanoma
- (2016) B R Patel et al. Oncogenesis
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma
- (2015) Lei Sun et al. FEBS LETTERS
- Insights into genetic alterations of liver metastases from uveal melanoma
- (2015) Conni McCarthy et al. Pigment Cell & Melanoma Research
- Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
- (2015) Peter Johansson et al. Oncotarget
- Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
- (2014) S. Leyvraz et al. ANNALS OF ONCOLOGY
- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
- (2014) Fa-Xing Yu et al. CANCER CELL
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- A recurrent germlineBAP1mutation and extension of theBAP1tumor predisposition spectrum to include basal cell carcinoma
- (2014) K.A.W. Wadt et al. CLINICAL GENETICS
- Recent developments in prognostic and predictive testing in uveal melanoma
- (2014) Matthew G. Field et al. CURRENT OPINION IN OPHTHALMOLOGY
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- c-MET expression in primary and liver metastases in uveal melanoma
- (2014) Faithlore P. Gardner et al. MELANOMA RESEARCH
- The Phosphoinositide 3-Kinase Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
- (2014) E. Musi et al. MOLECULAR CANCER THERAPEUTICS
- Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
- (2013) Sander Kelderman et al. ACTA ONCOLOGICA
- Single Nucleotide Polymorphism Array Analysis of Uveal Melanomas Reveals That Amplification of CNKSR3 Is Correlated With Improved Patient Survival
- (2013) Sarah L. Lake et al. AMERICAN JOURNAL OF PATHOLOGY
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma
- (2013) Katie A Matatall et al. BMC CANCER
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity
- (2013) Adriana Amaro et al. EUROPEAN JOURNAL OF CANCER
- Hypoxia inducible factor pathway inhibitors as anticancer therapeutics
- (2013) Sarah K Burroughs et al. Future Medicinal Chemistry
- Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
- (2013) G. Ambrosini et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
- (2013) O. Surriga et al. MOLECULAR CANCER THERAPEUTICS
- Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
- (2013) X Chen et al. ONCOGENE
- Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
- (2013) Makoto Yoshida et al. Pigment Cell & Melanoma Research
- A BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers
- (2013) Lauren G. Aoude et al. PLoS One
- Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
- (2013) H. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
- (2013) Helena Pópulo et al. PeerJ
- Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma Patients
- (2012) A. Klingenstein et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
- (2012) G. Ambrosini et al. CLINICAL CANCER RESEARCH
- c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential
- (2012) Xinqi Wu et al. MELANOMA RESEARCH
- A pilot study of sunitinib malate in patients with metastatic uveal melanoma
- (2012) Amit Mahipal et al. MELANOMA RESEARCH
- Ipilimumab activity in advanced uveal melanoma
- (2012) Muhammad Adnan Khattak et al. MELANOMA RESEARCH
- Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
- (2012) Erika von Euw et al. Molecular Cancer
- Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF- B Pathways
- (2012) X. Wu et al. MOLECULAR CANCER THERAPEUTICS
- A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors
- (2012) Jose P. Vaqué et al. MOLECULAR CELL
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Genetic and molecular characterization of uveal melanoma cell lines
- (2012) K. G. Griewank et al. Pigment Cell & Melanoma Research
- Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families
- (2012) Ching-Ni Jenny Njauw et al. PLoS One
- Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
- (2012) Shailender Bhatia et al. PLoS One
- Radioembolization as Salvage Therapy for Hepatic Metastasis of Uveal Melanoma: A Single-Institution Experience
- (2011) Carin F. Gonsalves et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
- (2011) S. Landreville et al. CLINICAL CANCER RESEARCH
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
- (2011) A. A. Tarhini et al. CLINICAL CANCER RESEARCH
- Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
- (2011) M. H. Abdel-Rahman et al. JOURNAL OF MEDICAL GENETICS
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- G q and Phospholipase C- : Turn On, Turn Off, and Do It Fast
- (2011) E. M. Ross Science Signaling
- Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
- (2010) H. Populo et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
- (2010) Helena Pópulo et al. MELANOMA RESEARCH
- Influence of Immune Privilege on Ocular Tumor Development
- (2010) Kyle C. McKenna et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- Effectiveness of Treatments for Metastatic Uveal Melanoma
- (2009) James J. Augsburger et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes
- (2009) Carol L. Shields ARCHIVES OF OPHTHALMOLOGY
- ADP-Ribosylation Factor 6 Regulates Glioma Cell Invasion through the IQ-Domain GTPase-Activating Protein 1-Rac1-Mediated Pathway
- (2009) B. Hu et al. CANCER RESEARCH
- The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation
- (2009) J.-P. Evenou et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Association of Cutaneous and Iris Nevi with Uveal Melanoma: A Meta-analysis
- (2009) Ezekiel Weis et al. OPHTHALMOLOGY
- Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications
- (2008) Mario A. Economou et al. ACTA OPHTHALMOLOGICA
- Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate into Clinical Efficacy of Imatinib Mesylate
- (2008) U. B. Hofmann et al. CLINICAL CANCER RESEARCH
- O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma
- (2008) Nicolas Penel et al. INVESTIGATIONAL NEW DRUGS
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started